http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108384757-B

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-06
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
filingDate 2018-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2021-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-108384757-B
titleOfInvention Method for preparing oxaliplatin-resistant cell line of human gallbladder cancer
abstract A method for preparing a human gallbladder cancer oxaliplatin drug-resistant cell line comprises the steps of inoculating human gallbladder cancer cells in a logarithmic growth phase into a DMEM culture solution containing newborn fetal calf serum for culture, adding oxaliplatin into the culture solution for induction, increasing the concentration when the cells recover normal growth, performing impact culture by using oxaliplatin when the cells can normally grow and passage at the concentration of 0.5 mu mol/L, replacing a culture medium with the oxaliplatin concentration of 0.5 mu mol/L for culture, performing impact again when the cells stably grow and passage, increasing the concentration, performing impact induction by using the oxaliplatin until the cells can grow in 10.0 mu mol/L of oxaliplatin, and obtaining the human gallbladder cancer oxaliplatin drug-resistant cell line capable of stably growing and passage in a culture system containing 10.0 mu mol/L of oxaliplatin. The method for establishing the oxaliplatin-resistant cell line of the gallbladder cancer is simple, convenient and easy to implement and short in establishment time; the resistance index is close to 20.
priorityDate 2018-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6857599
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415133005

Total number of triples: 13.